As of January 22, 2025, Rapport Therapeutics (RAPP) has a market cap of $0.50 billion USD. According to our data, Rapport Therapeutics is ranked No.6105 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.50 B |
-22.32%
|
Dec 31, 2024 | $0.65 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Sage Therapeutics
SAGE
|
$0.43 B |
-0.000 M
|
USA
|
Axsome Therapeutics
AXSM
|
$4.96 B |
0.000 M
|
USA
|
Intra-Cellular Therapies
ITCI
|
$13.51 B |
-0.000 M
|
USA
|
Biohaven Pharmaceutical
BHVN
|
$4.10 B |
-0.000 M
|
USA
|
ACADIA Pharmaceuticals
ACAD
|
$2.96 B |
-0.000 M
|
USA
|
Neurocrine Biosciences
NBIX
|
$14.86 B |
-0.000 M
|
USA
|
Alkermes
ALKS
|
$4.89 B |
-0.000 M
|
Ireland
|
Jazz Pharmaceuticals
JAZZ
|
$7.31 B |
0.000 M
|
Ireland
|
Supernus Pharmaceuticals
SUPN
|
$2.11 B |
-0.000 M
|
USA
|
Vanda Pharmaceuticals
VNDA
|
$0.25 B |
-0.000 M
|
USA
|
Minerva Neurosciences
NERV
|
$14.76 M |
0.000 M
|
USA
|
Otsuka Holdings
4578.T
|
$27.47 B |
-0.048 B
|
Japan
|
Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
Market Cap | = | RAPP Stock Price | * | RAPP Shares Outstanding |
= | $13.78 | * | 36.58 M | |
= | $0.50 B |